PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension.
نویسندگان
چکیده
REFERENCES 1 Sekizawa K, Ujiie Y, Itabashi S, Sasaki H, Takishima T. Lack of cough reflex in aspiration pneumonia. Lancet 1990; 335: 1228–1229. 2 Nakagawa T, Sekizawa K, Arai H, et al. High incidence of pneumonia in elderly patients with basal ganglia infarction. Arch Intern Med 1997; 157: 321–324. 3 Arai T, Yasuda Y, Toshima S, Yoshimi N, Kashiki Y. ACE inhibitors and pneumonia in elderly people. Lancet 1998; 352: 1937–1938. 4 Ohkubo T, Chapman N, Neal B, et al. Effects of an angiotensinconverting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 2004; 169: 1041–1045. 5 Arai T, Sekizawa K, Ohrui T, et al. ACE inhibitors and protection against pneumonia in elderly patients with stroke. Neurology 2005; 64: 573–574. 6 Chan WK, Chan TY, Luk WK, et al. A high incidence of cough in Chinese subjects treated with angiotensin converting enzyme inhibitors. Eur J Clin Pharmacol 1993; 44: 299–300.
منابع مشابه
Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report
BACKGROUND Portopulmonary hypertension (PPHTN) is a severe complication in liver cirrhosis. PDE5 inhibitors lower pulmonary arterial pressure (PAP) in PPHTN. However, their effect on portal hypertension has not yet been investigated. CASE PRESENTATION A 55 year old male patient presented with PPHTN and alcoholic liver cirrhosis. 10 mg of Tadalafil, a PDE5 inhibitor with a long half-life, was ...
متن کاملBeneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up
Non-selective beta-blockers are the mainstay of medical therapy for portal hypertension in liver cirrhosis. Inhibitors of phosphodiesterase-5 (PDE-5-inhibitors) reduce portal pressure in the acute setting by > 10% which may suggest a long-term beneficial effect. Currently, there is no available data on long-term treatment of portal hypertension with PDE-5-inhibitors. This case of a patient with...
متن کاملDrug Therapy in Patients with Chronic Thromboembolic Pulmonary Hypertension
Background: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) results from the obstruction of predominantly major pulmonary vessels by organized blood clots and is one of the causes of pulmonary hypertension. The disease is still underdiagnosed and the true prevalence is not clear. The objective of this study was to determine the clinical characteristics and current management of patients w...
متن کاملPulmonary vascular disorders in portal hypertension.
The wide spectrum of pulmonary vascular disorders in liver disease and portal hypertension ranges from the hepatopulmonary syndrome characterized by intrapulmonary vascular dilatations, to pulmonary hypertension (portopulmonary hypertension), in which pulmonary vascular resistance is elevated. Since hepatopulmonary syndrome and portopulmonary hypertension have been reported in patients with non...
متن کاملVenous outflow obstruction and portopulmonary hypertension after orthotopic liver transplantation
PATIENT Female, 54 FINAL DIAGNOSIS: Suprahepatic inferior vena cava anastomosis stricture Symptoms: Ascites • fatigue • lower limb edema • hepatomegaly MEDICATION - Clinical Procedure: - Specialty: Transplantology • Critical Care Medicine. OBJECTIVE Unusual clinical course. BACKGROUND Suprahepatic inferior vena cava anastomosis stricture is an unusual vascular complication after orthotopi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The European respiratory journal
دوره 29 1 شماره
صفحات -
تاریخ انتشار 2007